Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Subscribe to Free Drug Patent Expiration Updates

Also available in a Drug Patent Expiration NewsletterRSS feed and on Drug Patent Expirations on TwitterTwitter

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: DUAC

« Back to Dashboard
Duac is a drug marketed by Stiefel and is included in one NDA. It is available from two suppliers.

The generic ingredient in DUAC is benzoyl peroxide; clindamycin phosphate. There are seventeen drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the benzoyl peroxide; clindamycin phosphate profile page.

Summary for Tradename: DUAC

Suppliers / Packagers: see list2

Pharmacology for Tradename: DUAC

Clinical Trials for: DUAC

Evaluation of Quality of Life, Efficacy, and Tolerance of Duac® Gel Compared to Differin® Gel in the Treatment of Acne
Status: Completed Condition: Acne Vulgaris

To Compare the Efficacy and Safety of Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel of CHL Versus DUAC® Gel
Status: Recruiting Condition: Acne Vulgaris

Evaluation of the Effectiveness, Safety, and Tolerability of Duac Akne Gel and Epiduo Gel in the Treatment of Facial Acne Vulgaris
Status: Completed Condition: Acne Vulgaris

A Study Comparing Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel to Duac® Topical Gel in the Treatment of Acne Vulgaris
Status: Completed Condition: Acne Vulgaris

DUAC® Early Onset Efficacy Study in Japanese Subjects
Status: Not yet recruiting Condition: Acne Vulgaris

A Study Comparing Aczone® Plus Differin® Versus Duac® Plus Differin® in Patients With Severe Facial Acne
Status: Completed Condition: Acne Vulgaris

Study Comparing Clindamycin Phosphate and Benzoyl Peroxide Gel to Acanya® Gel and Both to a Vehicle Control in the Treatment of Acne Vulgaris
Status: Completed Condition: Acne Vulgaris

Combination Therapy With Differin® Gel 0.3% and Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris
Status: Completed Condition: Acne Vulgaris

A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Facial Acne
Status: Completed Condition: Acne Vulgaris

Safety and Tolerability of Acanya Gel in Combination With Atralin Gel for Acne Vulgaris
Status: Active, not recruiting Condition: Acne Vulgaris

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
benzoyl peroxide; clindamycin phosphate
GEL;TOPICAL050741-001Aug 26, 2002RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: DUAC

Drugname Dosage Strength RLD Submissiondate
clindamycin phosphate and benzoyl peroxideGel1% / 5%Duac12/11/2008
« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn